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renal failure seems to be dependent on the insufficiency degree,
The pathophysiological modifications underlying chronic
which will determine the moment to start therapy. As there is yet
limited information about animal models of moderate chronic
renal failure, we intended to perform a complete characterization
of the hematological and cardio-renal alterations induced by par-60	
tial nephrectomy. Blood samples from control and chronic renal
failure rats were collected at 0, 3, 9, and 15 weeks in order to
evaluate renal function, hematological parameters, iron metabo-
lism, blood lipids, peripheral sympathetic nervous system, and
inflammatory and redoz status markers. BP, tissues trophy65	
indexes, and kidney histomorphology were also assessed. Our
data are consistent with a sustained moderate degree of chronic
renal failure with a quickly compensated modest anaemia,
though presenting iron metabolism disturbances. Despite the rea-
sonable degree of functionality of the remnant kidney, as sug-
70	
gested by the anaemia correction and by the kidney hypertrophy
and moderate lesions, several important cardiovascular modifica-
tions were developed. Our model presented hypertension, dyslip-
idemia, erythropoietic disturbances, sympathetic activation, and
oxidative stress. This model might be a good tool to study the
cellular/molecular mechanisms underlying moderate stages of
chronic renal failure and to evaluate the therapeutic efficacy for
prevention and treatment/correction of cardio-renal anaemia syn-
dromes and complications in early stages.
75	
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metabolism disturbance, white blood cell activation,
oxidative stress and sympathetic over-activation."-61
However, the pathophysiological alterations seems to be
dependent on the renal failure degree, which will also 90
determine the moment to initiate hemodialysis and recom-
binant erythropoietin (rhEPO) therapies, for correction of
anaemia as well as its success. Therefore, cardiovascular
events, renal failure, and premature death can be better
prevented or delayed if earlier identified and treated for 95
CKD.161
Animal models of CRF, achieved by a reduction in
nephron number, create the possibility of testing in vivo
the mechanisms associated to renal dysfunction, and might
be essential to study the complications associated with
CRF as well as the efficacy of therapeutics to prevent or 100
delay adverse effects. The most commonly used tech-
niques include surgical resection of the tissue (partial
nephrectomy) and infarction, t71 but there is yet limited
information about its complete characterization, namely
for moderate CRF stages, which will restrict the research 105
on the molecular/cellular mechanism underlying the car-
dio-renal-anaemia syndrome, as well as its therapeutics.
There is some evidence that the infarction model in rats
presents a significant increase in proteinuria, hypertension
and glomerulosclerosis when compared with the model of 110
simple tissue excision (with equivalent renal mass reduc-
tion). isi This suggests that partial nephrectomy can pro-
vide a better model of renal failure in rat. (71 Furthermore,
there is some evidence of a good inter-individual variability
of uremia in this model of CRF. However, it is difficult to 115
standardize it, due to the lack of consistency of nephron
mass reduction and, thus, to reach the desired degree of
uremia.
The literature describes some features of distinct CRF
models in the rat t7-I21; however, they have been mainly 120
focused on parameters related to renal function and to
basic hematological studies, and even less is known about
moderate renal failure models. Therefore, without a
INTRODUCTION
Chronic kidney disease (CKD) worsens spontane-
ously and progressively as the number of functioning
nephrons decreases below a certain threshold. In humans,
CKD has been associated with a large number of alter-
ations, namely anaemia, hypertension, inflammation, iron




At the beginning of the experiments and at 3, 9, and
15 weeks after the surgical partial nephrectomy, the rats
were subjected to intraperitoneal anesthesia with a 2 mg/kg
13W of a 2:1 (v:v) 50 mg/mL ketamine (Ketalar®, Parke-
Davis, Lab., Pfizer Lda, Seixal, Portugal) solution in 2.5%
165 chlorpromazine (Largactil®, Rhdne-Poulenc Rorer, Lab
VitOria, Amadora, Portugal). Blood samples were immedi-
ately collected by venipuncture from the jugular vein into
syringes without anticoagulant (for serum samples
Serum total cholesterol (Total-c), high-density lipo- 200
protein cholesterol (HDL-c), low-density lipoprotein cho-
lesterol (LDL-c) and triglycerides (TGs) were analyzed on
a Hitachi 717 analyser (Roche Diagnostics Inc., Massa-
chuasetts, USA) using standard methods. LDL-c/HDL-c
and Total-c/HDL-c were used as atherogenic and cardio-
vascular risk indexes. 	 205
Iron Metabolism
Serum iron concentration was determined using a col-
orimetric method (Iron, Randox Laboratories Ltd., North
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consistent characterization and of a further comparison
125 with the human pathophysiology of moderate CKD, the
research on the molecular and cellular mechanisms under-
lying the cardio-renal-anaemia syndrome and its therapeu-
tics will remain limited.
The aim of our study was to perform a larger charac-
terization of this model by studying both hematological
and cardio-renal alterations in a rat model of moderate
CRF induced by partial (3/4) nephrectomy during a follow-up
period of 15 weeks, focusing on sympathetic activity,
130 inflammation, and oxidative stress.
MATERIALS AND METHODS
135 Animals and Experimental Protocol
collection) or with the appropriate anticoagulant: EDTA,
heparin, or a solution of acid citrate-dextrose (ACD). 170
Blood was centrifuged (160 g for 10 min. at 20°C) to
obtain the PRP, which was then centrifuged (730 g for
10 min. at 20°C) to obtain the platelet pellet and the PPP.
In order to maintain a normal volemia, thus ensuring that
results were not changed by the amount of blood collected,
the following parameters were analyzed only at the final
time (15 weeks) in a 10 ml blood sample collected from 175
rats under the anesthesia listed previously: circulating
catecholamines contents and inflammatory and redox sta-




Male Wistar rats (Charles River Lab., Inc., Barcelona,
Spain) weighing ± 275 g were maintained in an air-
conditioned mom, subjected to 12 h dark/light cycles and
given standard rat chow (IPM-R20, Letica, Barcelona,
Spain) and free access to tap water. Animal experiments
were conducted according to the European Communities
Council Directives on Animal Care.
The rats were divided into two groups (seven rats
each): a control group, and a group with surgical CRF
induced by a two-stage (3/4) nephrectomy. First, about
half of the left kidney was removed by left flank incision;
one week later, the right kidney was removed through
identical procedure. Control sham-operated rats were not
required based on our preliminary studies that demon-
strated a similar pattern for hematological and renal
parameters with the non-operated controls after nine
weeks, All of the animals have completed the 15-week
protocol. Body weight (BW) was monitored during the
study and blood pressure (BF') and heart rate (HR) mea-
sures using a tail-cuff sphygmomanometer LE 5001 (Letica,
Barcelona, Spain).
The rats were sacrificed by cervical dislocation, and
the heart, adrenals, kidneys, and liver were immediately
removed, placed in ice-cold Krebs' buffer, and carefully
cleaned of adherent fat and connective tissue. The BW,
the whole heart weight (I-1W), the left ventricle weight
(LVW), the two adrenals weight (AW), and the kidney and
liver weights were measured in all the rats under study in 185
order to be used as trophy indexes. Kidney histomor-




Renal and Liver Function
Serum creatinine, urea, and uric acid concentrations
were used as renal function indexes, and serum aspartate
aminotransferase (AST) and alanine aminotransferase 195
(ALT) levels were assessed for liver evaluation, through
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210 Ireland, UK), whereas serum ferritin and transferrin were




Red blood cell (RBC) count, hematocrit, hemoglobin
(Hb) concentration, hematological indices [mean cell vol-
ume (MCV), mean cell Hb (MCH) and mean cell I-lb con-
centration (MCHC)], red cell distribution width (RDW),
reticulocyte count, immature reticulocyte fraction (IRF),
platelets count, platelets indices [mean platelet volume
220 (MPV), platelet distribution width (PDW) and plaquetocrit
(PCT)), and total and differential white blood cell (WBC)
counts were assessed in whole blood EDTA by using
an automatic Coulter Counter® (Beckman Coulter Inc.,
California, USA). Serum erythropoietin was measured by
225 using an immunoassay kit (R&D Systems, Minneapolis,
Minnesota, USA). Results were expressed in pg/mL.
Catecholamine Assay
Norepinephrine (NE) and epinephrine (E) concentra-
tions in plasma, platelet, adrenals, and kidney were evalu-
230 ated by high-performance liquid chromatography with
electrochemical detection (HPLC-ED), according to previ-
ously described, t131 using appropriate standards (Sigma
Chemical Co. (St. Louis, Missouri, USA) and software
(Gilson 710). Concentrations were expressed in ng/mL for
235 plasma and platelets, ug/g wet tissue for adrenals, and ng/g
for kidney.
Inflammatory Markers
Serum levels of interleukin 2 (IL-2), IL-10, trans-
forming growth factor 01 (TGF-01), and tumor necrosis
240 factor a (TNF-a) were measured by ultrasensitive Quan-
tikine® ELISA kits (R&D Systems, Minneapolis, Minne-
sota, USA). Serum C-reactive protein (CRP) was
determined by using an ELISA kit from Helica Biosys-
tems, Inc. (Fullerton, California, USA). All assays were
245 performed in duplicate.
Redox Status
The thiobarbituric acid reactive-species (TBARs) assay
was used to assess serum products of lipid peroxidation,
namely malondialdehyde (MDA)." 41 Ferric reducing anti-
oxidant potential (FRAP) assay was used to estimate serum
250 total antioxidant status (TAS). [151 Serum 3-nitrotyrosine
(3-NT), which is an index of peroxynitrite formation, was
measured through an immunoassay (HyCult biotechnology
Uden, Netherlands).
Statistical Analysis
For statistical analysis, we used the Statview 4.53 255
software from Abacus Concepts Inc. (Berkeley, Califor-
nia, USA). Results are presented as means ± standard error
of means (SEM). Comparisons between groups and
between different times of evaluation were performed
using one-way ANOVA and Fisher's test. Significance
was accepted at p less than 0.05.	 260
RESULTS
Biochemical and Hematological Data 	 265
In Tables 1 and 2, we present the biochemical and
hematological changes for CRF and control rats, before
starting experiments and along the experimental period
(at 3, 9, and 15 weeks after partial nephrectomy). The 270
results were analyzed in order to study the alterations
associated with a moderate CRF during 15 weeks of fol-
low-up, as compared to the control group. In CRF rats,
three weeks after the partial (3/4) nephrectomy, a statisti-
cally significant increase in serum urea and creatinine 275
concentrations were found. This increase in renal func-
tion markers remained high along the following 12 weeks
(see Table I). Concerning liver function markers, a sta-
tistically significant increase was found in renal failure
rats for AST and ALT, particularly for the former at 280
9 weeks of the experimental period; at the end of experi-
ments (15 weeks), only AST activity was still signifi-
cantly higher. CRF rats presented alterations in the
lipidic profile, namely, a progressively increase in Total-
c, TGs, and HDL-c (see Table I). Iron status evaluation 285
revealed in CRF rats a progressively increase in ferritin
serum levels, which reached statistical significance in the
last evaluation. On the contrary, transferrin serum levels
were significantly lower three weeks after surgical proce-
dure, and remained lower during the following 12 weeks 290
of follow-up (see Table 1).
In relation to hematological data, three weeks after
nephrectomy, the CRF animals showed a statistically sig-
nificant decrease for RBC count, Hb, and hematocrit,
alongside a significantly increase in RDW and in platelet 295
count (see Table 2). These parameters were already simi-
lar to those of the control at 9 weeks after surgical inter-
vention and remained stable until the end of the follow-up
period. A trend to lower serum EPO levels was obtained in
the CRF rats (19.43±3.05 pg/mL) vs. the control (22.25 ±
1.00 pg/mL) at the final time, but not reaching statistical
significance.
No statistically significant differences were found 300
for total WBC counts; however, neutrophil and eosinophi I
Cardio-Renal Characterization of Moderate CRF	 5
Table 1
Biochemical changes in a rat model of moderate CRF during a follow-up period of 15 weeks
Before 3/4 N
All the rats
3 weeks after 3/4 N 9 weeks after 3/4 N 15 weeks after 3/4 N
Control CRF Control CRF Control CRF
Renal function
Creatinine (imoUL) 36.24 ± 1.78 35.36 ± 1.77 73.37 ± 3.541 29.17 ± 0.88 71.60 ± 4.42? 39.78 ± 1.77 80.44 ± 5.3*
Urea (mmol/L) 14.63 ± 0.24 13.99 ± 0.21 25.34 ± a95* 12.32 ± 0.48 25.99 ± 0.861 13.93 ± 0.56 24.21 ± 1.01*
Uric acid (Ismol/L) 35.69 ± 3.57 30.93 ± 2.97 27.36 ± 2.37 20 22 + 3 57 23.79 ± 2.34 36.88 ± 9.52 28.55 ± 5.35
Hepatic function
AST (1U/L) 68.25 ± 4.73 44.11 ± 3.42 56.70 ± 3.46 51.37 ± 1.21 72.00 + 3.97t 81.00 ± 8.35 141.40 + 10.831
ALT (IU/L) 34.00 ± 2.32 32.70 ± 2.31 29.33 ± 1.73 25.32 ± 1.35 39.60 + 1.63 1 33.67 ± 2.32 36.00 ± 2.67
Lipid profile
Total-c (mmol/L) 1.40 ± 0.04 1.33 ± 0.04 1.87 ± 0.11* 1.14±0.08 2.18±0.171 1.43 ± 0.10 2.88 + 0.131
HDL-c (mmol/L) 1.16 ± 0.03 1.08 ± 0.03 1.49 ± 0.07* 0.89 ± 0.07 1.75+ 0.10 1.10 ± 0.07 2.09± 0.111
LDL-c (mmol/L) 0.54 ± 0.02 0.50 ± 0.03 0.33 ± 0.031 0.45 ± 0.03 0.41 ± 0.04 0.44 ± 0.03 0.41 ± 0.02
TGs (mmol/L) 1.49 ± 0.06 1.43 ± 0.10 0.95 ± 0.09 1.25 ± 0.12 1.83 ±0.40 1.57 ± 0.24 2.34 ± 0.43*
LDL-c/HDL-c 0.47 ± 0.03 0.48 ± 0.04 0.22 ±0.021 0.53 ± 0.04 0.25 ± 0.051 0.40 ± 0.05 0.20 ± 0.02*
Total-c/HDL-c 1.21 ±0.02 1.24 ± 0.02 1.21 ±0.02 1.29 ± 0.04 1.24 ± 0.02 130 ± 0.04 1.38 ± 0.05
Iron metabolism
. Iron (µunol/L) 27.42 ± 2.31 19.49 ± 2.95 26.00 ± 1.56 34.77 ± 1.02 27.79 ± 1.34 27.60 ± 4.82 22.29 ± 2.13
Perritin (mmol/L) 28.38 ± 3.03 27.01 ± 3.12 40.36 ± 2.51 22.49 ±2.34 47.91 ± 4.80 29.03 ± 8.27 55.41 ± 11.95*
Transferrin (g/L) 130 ± 0.04 131 ±0.04 0.18 ± 0.031 1.30 ± 0.03 1.06 ± 0.06t 1.20 ± 0.08 0.81 ±0.111
Results are mean ± SEM of n = 7 rats/group.
< 0.05, tp < 0.01, and tp < 0.001 vs. the control group.
Abbreviation: N = nephrectomy.
counts increased progressively in renal failure rats. In
305 this group, basophil counts increased three weeks after
chirurgic procedure, and decreased progressively dur-
ing the remaining follow-up period, and monocyte
counts increased only in the last laboratorial evaluation
(see Table 2).
310
Blood Pressure, Heart Rate, Tissue Trophic Index,
and Kidney Histomorphology
At the end of the experimental protocol, a statistically
significant increase in SBP, DBP, MBP, and HR were
found in CRF rats, together with increment in heart and
LV ventricle, without statistically significant differences
in tissue trophic indexes (see Table 3).
The kidney morphology of the renal failure rats
was distinct from that of the controls: the glomerular
capillary tufts of the renal failure rats were hypercellu-
lar, with an increment of the glomerular volume; the
Bowman space was also higher; the interstitial region
was lower due to tubular atrophy, together with
expansion of proximal convoluted tubules (data not
shown).
Catecholamine Measures
Concerning sympathetic activity, CRF rats presented a 325
statistically significant increase in plasma and kidney NE,
and a decrease in platelet content together with a significant
reduction in platelet and adrenals E concentrations, and a
concomitant increment in plasma E (see Figure 1).
Redox Status and Inflammatory Profile
330
No statistically significant alterations were found
between the two rats groups for MDA and TAS, but a
significantly higher serum concentration of 3-NT was
found. Concerning the inflammatory profile, we observed
no significant differences between the two groups for 335
CRP, IL-I/3, IL-2, and TNF-a, except for TGF-131, which




The CKD is a major public health problem throughout




Hematological changes in a rat model of moderate CRF during a follow-up period of 15 weeks
Before V. N All
the rats
3 weeks after s% N 9 weeks after Vi 15 weeks after Ye N
Control CRF Control CRF Control CRF
RBC parameters
RBC (x1012/L) 7.32 ± 0.12 7.13 ± 0.11 6.18 ± 0.12* 6.39 ± 0.08 7.25 ± 0.19 7.44 ± 0.10 6.91 ± 0.14
lib (g/L) 138.21 ± 1.42 135.23 ± 2.12 114.21 ± 2.23* 129.04 ± 1.17 137.11 ± 2.18 139.44 ± 3.61 134.39 ± 2.01
Haematocrit (pp of 1.0) 0.395 ± 0.005 0.386 ± 0.005 0.328 ± 0.006* 0.363 ± 0.005 0.402 ± 0.002 0.409 ± 0.007 0.395 ± 0.006
MCV (fL) 53.95 ± 0.62 54.71 ± 0.53 53.09 ± 0.48 57.04 ± 0.64 55.54 ± 0.72 55.04± 1.32 57.27 ± 0.66
MCH (pg) 18.85 ± 025 19,23 ±023 1849 ± 0.17 20.20 ± 0.25 18.96 ± 0.36 18.74 ± 0.61 19.48 ± 0.28
MCHC (g/L) 349.32 ± 1.91 349.09 ± 2.00 348.42 ± 1.27 354.34 ± 1.49 341.35 ± 3.31 340.39 ± 3.72 340.01 ± 3.04
ROW (pp of 1.0) 0.133 ± 0.004 0.132 ±.0.003 0.153 ± 0.004* 0.126 ± 0.004 0.130 ± 0.002 0.149 ± 0.004 0.135 ± 0.002
Reticulocytes (x1091L) 389.01 ±29.10 393.11 ± 22.97 423.09 ± 20.01 379.11 ± 39.95 392.09 ± 34.04 383.98 ± 28.97 326.09 ± 27.02
IRF (pp of 1.0) 0.0038 ± 0.0002 0.0039 ± 0.0003 0.0041 ± 0.0002 0.0052 ± 0.0007 0.0042 ± 0.0005 0.0038 ±0.0001 0.0056 ± 0.0009
WBC parameters
WBC (x I o9n.) 6.87 ± 1.19 6.51 ± 1.02 6.69 ± 0.38 5.14 ± 0.91 6.39 ± 0.29 5.14 ± 0.22 5.53 ± 0.85
Neutrophils (x109/L) 0.08 ± 0.01 0.07 ± 0.01 0.10 ± 0.01 0.05 ± 0.01 0.25 ± 0.17* 0.07 ±0.01 0.52 ± 0.31*
Lymphocytes (x109/L) 5.82 ± 1.04 5.51 ±0.81 4.38 ± 0.43 4.37 ± 0.79 4.86 ± 0.34 4.32 ± 0.81 4.65 ± 0.74
Basophils (x109/L) 1.15 ± 0.33 1.01 ±0.22 1.89 ± 0.30* 0.65 ± 0.15 1.25 ± 0.23* 0.91 ± 0.52 0.29 ± 0.18*
Eosinophils (x109/L) 0.012 ± 0.002 0.015	 0.003 0.023 ± 0.003 0.015 ±0.003 0.028 ± 0.004* 0.023 ± 0.007 0.064 ± 0.032*
Monocytes (x109/L) 0.007 ±0.002 0.006 ± 0.002 0.009 ± 0.003 0.005 ± 0.002 0.001 ± 0.001 0.004 ± 0.002 0.018 ± 0.010*
Platelet parameters
Platelets (x109/L) 980.50 ± 22.79 973.41 ± 22.62 1203.80 ± 47.93* 943.87 ± 32.60 938.43 ± 49.85 980.40 ± 33.07 943.85 ± 78.49
PCT (pp of 1.0) 0.0057 ±0.0002 0.0056 ± 0.0002 0.0066 ±0.0002* 0.0054 ± 0.0002 0.0051 ± 0.0002 0.0058 ± 0.0002 0.0056 ± 0.0003
MPV (fL) 5.83 ± 0.17 5.73 ± 0.12 5.53 ± 0.07 5.69 ± 0.07 5.50 ± 0.08 5.90 ± 0.14 5.70 ± 0.11
PDW (pp of 1.0) 0.162 ± 0.002 0.162 ± 0.002 0.160 ± 0.001 0.163 ± 0.002 0.160 ± 0.002 0.167 ± 0.003 0.166 ± 0.002
Results are mean ± SEM of n = 7 rats/group.
*p < 0.05, tp < 0.01, and tp < 0.001 vs. the control group.
Abbreviation: N = nephrectomy.
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Table 3
Cardio-renal characterization, inflammatory markers, and redox
status profile in a rat model of moderate CRF after 15 weeks
of experimental study
Control (n = 7) CRF(n = 7)
Blood pressure and HR
SBP (mmHg) 114.88 ± 3.08 143.07 ± 4.61t
DBP (mmHg) 99.11 ± 1.76 123.31 ± 12.381
NNW (mmHg) 104.33 ± 1.89 129.64 ± 9.79t
HR (beats/min.) 339.12 ± 6.28 391.89 ± 12.00t
Body and tissue weights
BW (Kg) 0.47 ± 0.02 0.46 ± 0.01
HW (g) 1.21 ± 0.03 1.46 ± 0.06*
LVW (g) 0 .57 ± 0.03 0.72 ± 0.04*
KW (g) 1.24 ± 0.04 1.94 ± 0.20
LW (g) 15.91 ±058 18.23 ± 0.77
AW (g) 0.09 ± 0.01 0.10 ± 0.01
Tissue trophy indexes
HW/13W (g/kg) 2.65 ±0.07 2.98 ± 0.10
• LVW/HW (g/kg) 0.47 ± 0.02 050 ± 0.02
LVW/BW (g/kg) LOS ± 0.11 1.17 ± 0.14
KW/BW (g/kg) 2.62 ± 0.05 3.96 ± 0.39
LW/BW (g/kg) 33.90 ± 0.10 38.80 ± 2.51
AW/BW (g/kg) 0.18 ± 0.02 0.20 ± 0.02
Inflammatory markers
CRP (p.g/mL) 24.78 ± 1.25 25.83 ± 0.66
IL-1(3(pg/mL) 26.52 ± 0.94 23.76±0.99
IL-2 (pg/mL) 36.28 ± 8.70 49.34 ± 3.43
TNF-a (pg/mL) 16.34± 1.81 15.75± 1.96
TGE-01 (pg/mL) 358.41 ± 34.52 544.42 ± 50.43*
Redox status profile
MDA (lxmol/L) 0.27 ± 0.05 0.34 ± 0.06
TAS (punol/L) 394.72 ±51.42 408.03 ± 23.62
MDA/TAS 0.56 ± 0.05 0.73 ± 0.21
3-NT (nmol/L) 15.66 ± 1.40 50.45 ± 3.221
Results are mean ± SEM of n = 7 rats/group.
*p < 0.05, tp < 0.01, and tp < 0.001 vs. the control group.
include rapid progression, with development of anaemia
and serious complications, namely cardiovascular events.
Early detection of renal failure and initiation of treatment
should contribute to prevent or delay some of those
360 adverse effects. t161 However, animal models of moderate
CRF, which might be good tools to study the pathophysio-
logical mechanisms underlying intermediary stages of
renal disease and the efficacy of therapeutics, remain to be
fully characterized.
365	 Our results have confirmed that the surgical partial (3/4)
nephrectomy produces a moderate but sustained stage of
CRF. Indeed, we observed a significant (but restrained)
increase in serum urea and creatinine concentrations three
weeks after the surgery that remained almost constant
during the following period (still significantly higher than
controls). Furthermore, the results observed for RBC and
reticulocyte counts were similar to those observed for
serum urea and creatinine along the follow-up period, fur-
ther supporting that a moderate stage of renal failure was
generated. RBC count was significantly lower three weeks
after nephrectomy, consistent with the development of
anaemia secondary to renal mass reduction; moreover, the
number of reticulocytes as well as the percentage of imma-
ture reticulocytes did not increase, which suggests a fail-
ure of the erythropoietic response mechanisms due to a
putative insufficient erythropoietin production associated
to the reduction in renal tissue. However, the anaemia was
notoriously transitory, as both RBC and reticulocyte val-
ues returned to normal values in the following evaluation
points (9 and 15 weeks of study), suggesting that our
model is a moderate (but yet functional) CRF. Further-
more, at the final time, the serum EPO levels were almost
unchanged between the control and the CRF rats. This pattem
is also confirmed by the low-grade histomorphological
changes (lesions) found in the kidneys of CRF rats. There
was also a trend to increased kidney weight (hypertrophy),
consistent with a compensated renal insufficiency. Similar
hypertrophy was obtained in other models of CRF induc-
tion, such as the 5/6 nephrectomized rats. /9-I21 Further-
more, the CRF rats presented a notable increment in serum
TGF-01 levels, which is in agreement with the mass 370
recovering of the remnant kidney, most probably due to
mechanisms of cell growth and differentiation, hypertrophy,
and apoptosis, which have been implicated in the chronic
kidney disease pathophysiologyilli
Iron-restricted erythropoiesis is a common clinical con- 375
dition in patients with CKD. Several causes were proposed
to underlie this situation, such as a functional iron defi-
ciency, inadequate dietary iron intake, blood loss during the
hemodialysis processes or from gastrointestinal tract (bleed-
ing), inadequate intestinal iron absorption, and inhibition of 380
iron mobilization from macrophages. 112-/6.181 In our study,
CRF rats presented serum iron values similar to those of the
control, and no significant changes were observed along the
experiments; however, a trend toward higher values of fer-
ritin were observed along the experiments and reached a 385
significantly higher value at the end (15 weeks). These
changes in fenitin were accompanied by a significant
reduction in transferrin (observed at 3 weeks and after-
ward), suggesting an inhibition in iron traffic, from mac-
rophages to erythroid cells: leading to the progressive 390
increase in iron storage, as shown by the progressive
increase in ferritin observed throughout the experiments.
This suggests that our moderate model of CRF could also be
used as a model of functional iron deficiency. Indeed, a
functional iron deficiency has been reported in CKD patient 395
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Figure I. Norepinephrine (NE) and epinephrine (E) contents in plasma, platelets, adrenals, and kidneys in a rat model of moderate
CRF after an experimental period of 15 weeks. Results are mean t SEM of n = 7 rats/group. *p< 0.05, "p < 0.01, and *a p < 0.001 vs.
the control group. Abbreviation:. NS = non-significant.
Concerning the other biochemical parameters, our
model demonstrated important changes in liver function
markers, with AST and ALT being significantly higher at 9
weeks and at the end of experiments in CRF rats, accompa-
nied by a trend to increased 'liver weight. We might hypothe-
size that renal dysfunction leads to a progressive deterioration
of liver function, but the exact interacting mechanism(s)
between the kidney and the liver deserve further clarification.
Furthermore, the increase in AST without changes in ALT,
which occuned at the end of experiments (15 wefts), might
reflect other non-hepatic dysfunctions, namely on the cardio-
renal axis, which is supported by other data from our work,
such as by the hyperirophic heart and kidneys.
Liver metabolism dysfunction could also play a role
in the lipid profile changes encountered in the CRF rats:
increased values of total-cholesterol, HDL-c, and TGs
400 without differences on LDL-c content, which might be
explained, at least in part, by the lack in cholesteryl ester
transfer protein (CETP), a feature of the rats. 1201 Lipid
abnormalities are found in CKD humans, and the preva-
lence of hyperlipidemia and metabolic syndrome is higher
405 than in the general population. L21.221 However, the risk of
cardiovascular disease in CKD patients varies depending
on the type of lipid abnormalities, the cause of renal dis-
ease, and the degree of reduction in glomerular filtration
rate (GFR).123I Our rat model reproduces the lipidic changes
410 encountered in CKD patients.12°431
Besides the anaemia secondary to renal failure, CKD
patients usually develop cardiac failure that further aggra-
vates renal disease. E24•5i This triad of dysfunctions, already
known as cardio-renal anaemia syndrome, is responsible 440
for the serious complications encountered in those patients.
Our study intended to clarify the degree of cardio-renal
complications associated with this model of moderate
renal failure. Hypertension is a well-established cause, a
common complication, and an important risk factor for the 445
progression of the cardiovascular complications and the
mortality of patients with CRF. L61 Our results confirmed
that condition, with increased SBP and DBP, together with
tachycardia and heart and left ventricle hypertrophy,
which should be due to additional effort to compensate the 450
renal function deterioration. The pathophysiology of this
hypertension is multifactorial. l261 Several authors conclude
that CRF also activates (through the renin-angiotensin
system) the sympathetic nervous system (SNS). 15.163 The
kidneys, strategically positioned, have dense sensory and 455
efferent sympathetic innervations, and can be the origin as
well as the target of overactivity of the SNS, which has
been convincingly shown in CRF animal models.t27i
Several studies showed that partially nephrectomized rats
developed a rapid increase of BP within a week after renal 460
ablation, while totally nephrectomized rats, in which afferent
sensory signals were removed, did not develop hyperten-
sion. This suggests that afferent signals from the disease
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kidneys are transmitted to the vasomotor control center in the
465 brain, thereby contributing to the increased BP. E5+271 In our
model of moderate renal failure, plasma NE and E contents
were increased, which might be caused by adrenal and plate-
let release, due to sympathetic system over activation and
platelet hyper-reactivity, respectively, both contributing to
470 cardiovascular and thromboembolic complications as well as
atherosclerosis found in CKD patientsP8'291
Other factors have been studied to clarify the causes of
this hypertension, including high levels of vasoconstrictors,
oxidative stress or nitric oxide (NO) reduction.163IJ In CRF
475 patients, oxidative stress and inflammation could play a cm-
cial role in the pathogenesis of the atherosclerosis, malnutri-
tion, and anaemia In our model of moderate renal failure, the
redox state seems to be unaltered (MDA/TAS ratio was
unchanged), which might be due to a proper compensation of
480 ROS formation by antioxidants. However, there was an
increased serum 3-NT value, which is a matter of peroxyni-
trite generation and thus might reflect an increased superox-
ide formation and a reduced NO availability, as this
dangerous oxidant is formed by the combination of both. In
485 this model, inflammation seem to be yet less relevant as,
except for an increment of TGF-$l, all of the other markers
were unchanged. The increment in ferritin, an acute phase
protein, might also be viewed as part of an inflammatory
state. However, the involvement of inflammation on this
490 model of moderate CRF should be further confirmed,
namely, by studies on the hypertrophic remnant kidney.
In conclusion, this model is consistent with a moder-
ate degree of renal failure (sustained during the follow-up
period) with a modest and quickly compensated anaemia,
495 though presenting a disturbance in iron metabolism.
Despite the reasonable degree of functionality of the rem-
nant kidney (1/4 of total mass), as suggested by the correc-
tion of anaemia as well as by the kidney hypertrophy and
the moderate structural modifications (lesions) observed,
several important cardiovascular modifications were devel-
oped. Therefore, our model presented hypertension, dyslipi-
500 dernia, erythropoietic disturbances, sympathetic activation,
and oxidative stress. This model might be a good tool to
study the cellular/molecular pathophysiological mecha-
nisms underlying moderate stages of chronic renal failure,
as occurs in humans, and, even more relevant, to evaluate
the efficacy of therapeutics for prevention, treatment, or
correction of cardio-renal anaemia syndromes and compli-
cations in early stages.
505
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